NCT03206814

Brief Summary

The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
480

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2021

Longer than P75 for not_applicable

Geographic Reach
2 countries

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 2, 2017

Completed
3.9 years until next milestone

Study Start

First participant enrolled

May 11, 2021

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

February 27, 2025

Status Verified

February 1, 2025

Enrollment Period

4.6 years

First QC Date

June 30, 2017

Last Update Submit

February 26, 2025

Conditions

Keywords

HypertensionAmbulatory Systolic Blood PressureHome Blood PressureESH-CARE APP

Outcome Measures

Primary Outcomes (1)

  • Ambulatory Systolic Blood Pressure

    Change in ambulatory 24h systolic blood pressure

    12 months

Secondary Outcomes (9)

  • Ambulatory Diastolic Blood Pressure

    12 months

  • Difference between Office Blood Pressure and Home Blood Pressure

    12 months

  • Left ventricular mass index

    12 months

  • Left ventricular hypertrophy

    12 months

  • Urinary albumin to creatinine ratio

    12 months

  • +4 more secondary outcomes

Study Arms (2)

Group 1 - Usual care

ACTIVE COMPARATOR

Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.

Other: Usual care

Group 2 - POST-strategy

EXPERIMENTAL

Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.

Other: POST-strategy

Interventions

Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.

Group 1 - Usual care

Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.

Group 2 - POST-strategy

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female subjects;
  • Age 18-80 years;
  • Either the patient or another person close to him/her should possess a smartphone compatible with the ESH CARE app and be capable of using it;
  • Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140/90 mmHg, and Ambulatory 24h ABP ≥130/80 mmHg

You may not qualify if:

  • eGFR \<45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009);
  • Severe uncontrolled hypertension (i.e. BP ≥200/120 mmHg despite treatment);
  • Known secondary hypertension;
  • Orthostatic hypotension (SBP fall \> 20 mmHg on standing);
  • Unstable clinical conditions or severe disease with short life expectation;
  • Known atrial fibrillation;
  • Hepatic disease as determined by either AST or ALT values \> 2 times the upper limit of normal;
  • History of gastrointestinal surgery or disorders which could interfere with drug absorption
  • History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years;
  • History of clinically significant autoimmune disorders such as systemic lupus erythematosus;
  • History of drug or alcohol abuse within the last 5 years;
  • History of non-compliance to medical regimens and/or patients who are considered potentially unreliable;
  • Dementia (clinical diagnosis);
  • Inability or unwillingness to give free informed consent;
  • Inability to use even simple communication technologies;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Private Hospital " Dr Raúl Matera"

Bahía Blanca, B8000, Argentina

RECRUITING

Argerich Hospital

Buenos Aires, C155 AHD, Argentina

RECRUITING

General San Martin Hospital of La Plata

La Plata, 1900, Argentina

RECRUITING

Spanish Hospital of Mendoza

Mendoza, M5501, Argentina

RECRUITING

British Sanatorium of Rosario

Rosario, S2000, Argentina

RECRUITING

Shanghai Institute of Hypertension

Shanghai, Huangpu, China

RECRUITING

Jiangsu Province Official Hospital

Jiangse, 210024, China

ACTIVE NOT RECRUITING

Ruijin Hospital North

Shanghai, 200025, China

RECRUITING

MeSH Terms

Conditions

Essential HypertensionHypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Gianfranco Parati, MD

    Istituto Auxologico Italiano

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gianfranco Parati, MD

CONTACT

Paulina Wijnmaalen, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Centralized reading of ECG, echocardiography and ABPM, blinded for treatment group assignment
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2017

First Posted

July 2, 2017

Study Start

May 11, 2021

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

February 27, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations